Unique ID issued by UMIN | UMIN000016344 |
---|---|
Receipt number | R000018971 |
Scientific Title | The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan, Efficient Identification of Actionable Cancer Genome Alterations in Advanced Non-Colorectal Gastrointestinal Cancer (SCRUM-Japan GI Screen 2015-01-Non-CRC) |
Date of disclosure of the study information | 2015/01/26 |
Last modified on | 2022/05/10 19:49:48 |
The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan, Efficient Identification of Actionable Cancer Genome Alterations in Advanced Non-Colorectal Gastrointestinal Cancer (SCRUM-Japan GI Screen 2015-01-Non-CRC)
SCRUM-Japan GI Screen 2015-01- Non-CRC
The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan, Efficient Identification of Actionable Cancer Genome Alterations in Advanced Non-Colorectal Gastrointestinal Cancer (SCRUM-Japan GI Screen 2015-01-Non-CRC)
SCRUM-Japan GI Screen 2015-01- Non-CRC
Japan |
Gastrointestinal cancer
Gastroenterology | Hepato-biliary-pancreatic medicine |
Malignancy
YES
To evaluate the frequency or characteristics of cancer genome alterations in advanced non-colorectal gastrointestinal cancers
Others
To evaluate the frequency or characteristics of cancer genome alterations in advanced non-colorectal gastrointestinal cancers,Quality of the specimen contributing to gene analysis
Frequency or characteristics of cancer genome alteration
Association between each cancer genome alterations and clinicopathological characteristics or prognosis,Quality of the specimen contributing to gene analysis
Observational
Not applicable |
Not applicable |
Male and Female
1) Patients with histologically confirmed or clinically suspected advanced cancer of following descriptions; 1.gastric or gastro-esophageal junction adenocarcinoma 2.Esophageal cancer(adenocarcinoma or squamous cell carcinoma) 3.Others (adenocarcinoma of small intestine, appendiceal adenocarcinoma, anal cancer, neuroendocrine carcinoma which includes mixed type with adenocarcinoma)
2) Planned to receive systemic chemotherapy for advanced disease
3) Presence or ability to acquire sufficient DNA for target sequencing
4) Written informed consent was obtained
1) Patient is judged by the investigator to be inappropriate for study participation for any reason.
1500
1st name | Takayuki |
Middle name | |
Last name | Yoshino |
National Cancer Center Hospital East
Gastrointestinal Oncology Division
277-8577
6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan
81-47-133-1111
tyoshino@east.ncc.go.jp
1st name | Kohei |
Middle name | |
Last name | Shitara |
National Cancer Center Hospital East
Gastrointestinal Oncology Division
277-8577
6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan
04-7133-1111
kshitara@east.ncc.go.jp
National Cancer Center Hospital East
SCRUM Japan
Other
National Cancer Center Institutional Review Board
5-1-1, tsukiji, chuo-ku, tokyo
0335422511
NCC_IRBoffice@ml.res.ncc.go.jp
NO
2015 | Year | 01 | Month | 26 | Day |
Unpublished
2952
Completed
2015 | Year | 01 | Month | 26 | Day |
2015 | Year | 04 | Month | 07 | Day |
2015 | Year | 04 | Month | 16 | Day |
2022 | Year | 03 | Month | 31 | Day |
2022 | Year | 03 | Month | 31 | Day |
Each cancer genome alterations and clinicopathological characteristics or prognosis,Quality of the specimen contributing to gene analysis
2015 | Year | 01 | Month | 26 | Day |
2022 | Year | 05 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018971
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |